Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Shaheer Khan, Jose Lutzky, Alexander N. Shoushtari, Joanne Jeter, Brian Marr, Thomas E. Olencki, Colleen M. Cebulla, Mohamed Abdel-Rahman, J. William Harbour, Naomi Sender, Alexandra Nesson, Shahnaz Singh-Kandah, Susana Hernandez, Jeanelle King, Manpreet S. Katari, Lyssa Dimapanat, Stephanie Izard, Grazia Ambrosini, Oliver Surriga, Alex J. RaiCodruta Chiuzan, Gary K. Schwartz, Richard D. Carvajal

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Introduction: Approximately 40% of patients with uveal melanoma (UM) will develop metastatic disease. Tumors measuring at least 12mm in basal diameter with a class 2 signature, as defined by a widely used gene expression-profiling test, are associated with significantly higher risk of metastasis, with a median time to recurrence of 32 months. No therapy has been shown to reduce this risk. Materials and Methods: This was a single-arm, multicenter study in patients with high-risk UM who received definitive treatment of primary disease and had no evidence of metastasis. Patients were consecutively enrolled to receive 12 four-week cycles of adjuvant crizotinib at a starting dose of 250mg twice daily and were subsequently monitored for 36 months. The primary outcome of this study was to assess recurrence-free survival (RFS) of patients with high-risk UM who received adjuvant crizotinib. Results: 34 patients enrolled and received at least one dose of crizotinib. Two patients were unevaluable due to early withdrawal and loss to follow-up, leaving 32 patients evaluable for efficacy. Eight patients (25%) did not complete the planned 48-week course of treatment due to disease recurrence (n=5) or toxicity (n=3). All patients experienced at least one adverse event (AE), with 11/34 (32%) experiencing a Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 AE. After a median duration of follow up of 47.1 months, 21 patients developed distant recurrent disease. The median RFS was 34.9 months (95% CI (Confidence Interval), 23-55 months), with a 32-month recurrence rate of 50% (95% CI, 33-67%). Analysis of protein contents from peripheral blood extracellular vesicles in a subset of patient samples from baseline, on-treatment, and off-treatment, revealed a change in protein content associated with crizotinib exposure, however without a clear association with disease outcome. Conclusions: The use of adjuvant crizotinib in patients with high-risk UM did not result in improved RFS when compared to historical controls. Analysis of blood extracellular vesicles revealed changes in protein content associated with treatment, raising the possibility of future use as a biomarker. Further investigation of adjuvant treatment options are necessary for this challenging disease.

Original languageEnglish (US)
Article number976837
JournalFrontiers in Oncology
StatePublished - Aug 29 2022


  • adjuvant therapy
  • crizotinib
  • extracellular vesicles
  • high-risk
  • uveal melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy'. Together they form a unique fingerprint.

Cite this